Anthropic confirms a Bay Area wet lab, then walks back the "drug discovery" framing

verifiedHealthcare

Friday, September 18, 2026

Confidence

Medium · — Reuters primary + CNBC, Engadget, TNW corroborating; scope, targets, and investment level undisclosed

Evidence

Reuters exclusive + on-record confirmation + spokesperson pushback

Reuters reported Anthropic has stood up a physical biology lab; life sciences head Eric Kauderer-Abrams confirmed it, then a spokesperson said it is not for drug discovery specifically.

The details

Anthropic added Novartis CEO Vas Narasimhan to its board and bought Coefficient Bio for ~$400M in stock.
The company declined to share size, staff, opening date, or biosafety level.

What it means

A frontier lab operating its own bench and refusing to name what it does there signals to every pharma partner that Anthropic is close enough to the science to want the data proprietary. The denial matters less than the hire list.

Reuters reported Anthropic has stood up a physical biology lab; life sciences head Eric Kauderer-Abrams confirmed it, then a spokesperson said it is not for drug discovery specifically.

Anthropic added Novartis CEO Vas Narasimhan to its board and bought Coefficient Bio for ~$400M in stock.
The company declined to share size, staff, opening date, or biosafety level.

Sources

Apply this today

The hands-on layer the brief points to: a workflow you can run, a tool to test, and today’s 60-second video.

Workflow of the day

Draft an AI Vendor Risk Brief from a CEO's Public Statements

Legal · tested · saves 60-90 minutes per vendor review

Full walkthrough →

Tool watch

Comp AI

Comp AI's continuous compliance play: does it change how you scope a SOC 2 engagement?

Read the breakdown →

▶ Watch today’s 60-second brief →

In this issue

← Back to brief

Get the next one in your inbox

One daily brief. Every story gets a hype verdict.

No spam. Unsubscribe anytime.

On this page

The details
What it means

In this issue

← Back to brief

Stat of the Day

–93%▼

agentic-payments rail volume, 2026

American Banker reports a specialized agentic-payments rail has lost 93% of its volume this year even as startups pile into the category — the rare demand-side number in an infrastructure-heavy narrative. Source.

Today’s Take

Today's slate reads as one thesis in four beats: labs are vertically integrating (Astra, Anthropic biology), the tools are already offensive against each other (Claude on OpenAI), the deployment claims are outrunning the disclosures (Ant International), and the buyers keep saying the agents are not ready to run alone (WSJ, AT&T, Crocs). The pattern is a supply side sprinting past a trust ceiling — and a rare demand number (–93%) that suggests the ceiling is real, not rhetorical. The near-term bet that works is boring: narrow, audited, human-supervised agents inside regulated workflows. Considered and passed: SoftBank's $25B Arm margin loan (Bloomberg primary but a leverage-mechanics story more than an agent story) and the BoE governor's financial-crime AI remarks (trade-press intermediary, no BoE primary transcript).

— Agentic desk

Never miss a signal

Join professionals getting the daily AI brief every weekday morning.

No spam · Unsubscribe anytime

No sponsored verdicts
Sources linked
Corrections public